Solid Biosciences Braces for Big Drop After DMD Data

SLDB stock is heavily shorted

by Karee Venema

Published on Feb 7, 2019 at 9:19 AM

Solid Biosciences Inc (NASDAQ:SLDB) could be on track for its worst day ever, after the life sciences company reported disappointing preliminary data for its Duchenne Muscular Dystrophy (DMD) gene therapy treatment. The study includes a planned dose escalation, and the company plans to move forward with a higher dosage.

In reaction to this early data, SLDB is bracing for a 72.9% drop this morning, and is set to open at an all-time low of $6.01 per share. If these pre-market losses hold, they would surpass the stock's 64.6% plunge on March 15 as Solid Biosciences' biggest one-day drop on record. Heading into today's trading, the equity was already down 16.6% year-to-date, and closed last night at $22.34.

One group of traders is cheering today's expected plunge. Short interest on SLDB jumped 23.2% in the two most recent reporting periods to a record 2.97 million shares. These bearish bettors will likely be sidelined until early next week, with the equity all but certain to land on the short-sale restricted list out of the gate.

Analysts have yet to weigh in on SLDB stock, but a round of bear notes could be on the horizon. Currently, three of six covering brokerages maintain a "strong buy" on the security, while the average 12-month priced target sits all the way up at $43.33.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The IRS Loopholes Retirees Need to Know
Click to continue to advertiser's site.
Karuna Quintuples; Coty Rises on Kylie Deal
Coty bought a sizable stake in Kylie Jenner's business
Call Buyers Stay Behind Huntsman
HUN stock is in focus this morning following bullish brokerage attention
The IRS Loopholes Retirees Need to Know
Click to continue to advertiser's site.